GlassScriptPhysician profile
Rusty T Dreksler
NPI 1780008045
$2,611.69
in general payments reported to CMS, 2019-2025
26 companies · $827 in 2025
The $827 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $636 · 2023: $534 · 2024: $615 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $619.20 | 2022-2025 | Erleada, Akeega, Carvykti |
| Ferring Pharmaceuticals INC. | $408.02 | 2024-2025 | Adstiladrin |
| Teleflex LLC | $195.45 | 2022-2025 | Urolift |
| Axonics, INC. | $181.03 | 2022-2023 | Axonics |
| Endo Pharmaceuticals INC. | $134.45 | 2022-2023 | Xiaflex |
| Urogen Pharma, INC. | $126.20 | 2023-2024 | Jelmyto |
| Abbvie INC. | $117.83 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.09 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $97.47 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $74.57 | 2022-2023 | Myrbetriq |
| Myriad Genetic Laboratories, INC. | $71.74 | 2023-2025 | Prolaris, Myrisk |
| Endo USA, INC. | $64.19 | 2024-2025 | Xiaflex, Aveed |
| Verity Pharmaceuticals INC. | $57.26 | 2024-2025 | Trelstar |
| Urovant Sciences INC | $54.50 | 2022 | |
| Dentsply Ih Ab | $54.01 | 2024-2025 | Lofric |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $49.50 | 2023-2024 | Pylarify |
| Tolmar, INC. | $36.41 | 2023-2025 | Jatenzo |
| Coloplast Corp | $26.15 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.64 | 2023 | |
| Merck Sharp & Dohme LLC | $21.76 | 2022 | |
| Elucent Medical | $19.17 | 2025 | |
| Accord Healthcare, INC. | $18.97 | 2022 | |
| Medtronic, INC. | $18.76 | 2024 | Interstim |
| Acerus Pharmaceuticals Corporation | $18.06 | 2022 | |
| Blue Earth Diagnostics | $13.75 | 2022 | |
| Allegis Pharmaceuticals, LLC | $11.51 | 2023 | Urimar-T Caps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rusty Dreksler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.